KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

TherapeuticsMD (TXMD) Revenue (2016 - 2025)

TherapeuticsMD's Revenue history spans 16 years, with the latest figure at $893000.0 for Q4 2025.

  • For Q4 2025, Revenue rose 33.88% year-over-year to $893000.0; the TTM value through Dec 2025 reached $3.0 million, up 71.61%, while the annual FY2025 figure was $3.0 million, 71.61% up from the prior year.
  • Revenue reached $893000.0 in Q4 2025 per TXMD's latest filing, up from $784000.0 in the prior quarter.
  • In the past five years, Revenue ranged from a high of $68.6 million in Q4 2022 to a low of $53000.0 in Q3 2023.
  • Average Revenue over 5 years is $8.2 million, with a median of $607000.0 recorded in 2024.
  • Peak YoY movement for Revenue: tumbled 99.27% in 2023, then skyrocketed 932.08% in 2024.
  • A 5-year view of Revenue shows it stood at $18.7 million in 2021, then soared by 267.09% to $68.6 million in 2022, then crashed by 99.27% to $502000.0 in 2023, then surged by 32.87% to $667000.0 in 2024, then surged by 33.88% to $893000.0 in 2025.
  • Per Business Quant, the three most recent readings for TXMD's Revenue are $893000.0 (Q4 2025), $784000.0 (Q3 2025), and $952000.0 (Q2 2025).